BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24376466)

  • 1. Highlights on novel technologies for the detection of antibodies to Ro60, Ro52, and SS-B.
    Infantino M; Bentow C; Seaman A; Benucci M; Atzeni F; Sarzi-Puttini P; Olivito B; Meacci F; Manfredi M; Mahler M
    Clin Dev Immunol; 2013; 2013():978202. PubMed ID: 24376466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-ENA profiles related with anti-SS-A/Ro. The detection of Ro52 and Ro60 according to the presence of SS-B/La, and ANA pattern and titer.
    González DA; Rodríguez CC; Armas LM; Varela AR; Rodríguez IM; Duarte MT; de León AC
    Immunol Lett; 2014 Sep; 161(1):6-12. PubMed ID: 24768604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of anti-Ro52, anti-Ro60 and anti-La antibodies with diagnostic, clinical and laboratory features in a referral hospital in Jerez, Spain.
    Menor Almagro R; Jurado Roger A; Rodríguez Gutiérrez FJ; Solís Díaz R; Cardiel MH; Salaberri Maestrojuan JJ
    Reumatol Clin; 2016; 12(5):256-62. PubMed ID: 26725021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Latest update on the Ro/SS-A autoantibody system.
    Schulte-Pelkum J; Fritzler M; Mahler M
    Autoimmun Rev; 2009 Jun; 8(7):632-7. PubMed ID: 19393201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Utility of Separate Anti-Ro60 and Anti-Ro52/TRIM21 Antibody Detection in Autoimmune Diseases.
    Robbins A; Hentzien M; Toquet S; Didier K; Servettaz A; Pham BN; Giusti D
    Front Immunol; 2019; 10():444. PubMed ID: 30915082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strong Association of the Myriad Discrete Speckled Nuclear Pattern With Anti-SS-A/Ro60 Antibodies: Consensus Experience of Four International Expert Centers.
    Röber N; Dellavance A; Ingénito F; Reimer ML; Carballo OG; Conrad K; Chan EKL; Andrade LEC
    Front Immunol; 2021; 12():730102. PubMed ID: 34675922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between multiplex assays for autoantibody detection in systemic lupus erythematosus.
    Hanly JG; Su L; Farewell V; Fritzler MJ
    J Immunol Methods; 2010 Jun; 358(1-2):75-80. PubMed ID: 20438730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical associations of the positive anti Ro52 without Ro60 autoantibodies: undifferentiated connective tissue diseases.
    Murng SHK; Thomas M
    J Clin Pathol; 2018 Jan; 71(1):12-19. PubMed ID: 28663326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Ro60 Seropositivity Determines Anti-Ro52 Epitope Mapping in Patients With Systemic Sclerosis.
    Gkoutzourelas A; Liaskos C; Mytilinaiou MG; Simopoulou T; Katsiari C; Tsirogianni A; Daoussis D; Scheper T; Meyer W; Bogdanos DP; Sakkas LI
    Front Immunol; 2018; 9():2835. PubMed ID: 30581434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical performance evaluation of a novel rapid response chemiluminescent immunoassay for the detection of autoantibodies to extractable nuclear antigens.
    Bentow C; Swart A; Wu J; Seaman A; Manfredi M; Infantino M; Benucci M; Lakos G; Mahler M
    Clin Chim Acta; 2013 Sep; 424():141-7. PubMed ID: 23727029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Ro52 and/or anti-Ro60 immune reactivity: autoantibody and disease associations.
    Zampeli E; Mavrommati M; Moutsopoulos HM; Skopouli FN
    Clin Exp Rheumatol; 2020; 38 Suppl 126(4):134-141. PubMed ID: 32083547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical associations of anti-SSA/Ro60 and anti-Ro52/TRIM21 antibodies: Diagnostic utility of their separate detection.
    Menéndez A; Gómez J; Escanlar E; Caminal-Montero L; Mozo L
    Autoimmunity; 2013 Feb; 46(1):32-9. PubMed ID: 23039326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease.
    Peene I; Meheus L; De Keyser S; Humbel R; Veys EM; De Keyser F
    Ann Rheum Dis; 2002 Oct; 61(10):929-33. PubMed ID: 12228166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune responses to Ro60 and its peptides in mice. I. The nature of the immunogen and endogenous autoantigen determine the specificities of the induced autoantibodies.
    Deshmukh US; Lewis JE; Gaskin F; Kannapell CC; Waters ST; Lou YH; Tung KS; Fu SM
    J Exp Med; 1999 Feb; 189(3):531-40. PubMed ID: 9927515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcellular redistribution and surface exposure of the Ro52, Ro60 and La48 autoantigens during apoptosis in human ductal epithelial cells: a possible mechanism in the pathogenesis of Sjögren's syndrome.
    Ohlsson M; Jonsson R; Brokstad KA
    Scand J Immunol; 2002 Nov; 56(5):456-69. PubMed ID: 12410795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies to Both Ro52 and Ro60 for Identifying Sjögren's Syndrome Patients Best Suited for Clinical Trials of Disease-Modifying Therapies.
    Armağan B; Robinson SA; Bazoberry A; Perin J; Grader-Beck T; Akpek EK; Kim J; Baer AN
    Arthritis Care Res (Hoboken); 2022 Sep; 74(9):1559-1565. PubMed ID: 33742788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-SSA Ro52/Ro60 antibody testing by immunodot could help the diagnosis of Sjogren's syndrome in the absence of anti-SSA/SSB antibodies by ELISA.
    Mekinian A; Nicaise-Roland P; Chollet-Martin S; Fain O; Crestani B
    Rheumatology (Oxford); 2013 Dec; 52(12):2223-8. PubMed ID: 24026249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA association of anti-Ro60 and anti-Ro52 antibodies in Sjögren's syndrome.
    Ricchiuti V; Isenberg D; Muller S
    J Autoimmun; 1994 Oct; 7(5):611-21. PubMed ID: 7530962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spreading of the immune response from 52 kDaRo and 60 kDaRo to calreticulin in experimental autoimmunity.
    Kinoshita G; Keech CL; Sontheimer RD; Purcell A; McCluskey J; Gordon TP
    Lupus; 1998; 7(1):7-11. PubMed ID: 9493142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Combined Anti-Ro52/TRIM21 and Anti-Ro60/SSA Antibodies With Increased Sjögren Disease Severity Through Interferon Pathway Activation.
    Bettacchioli E; Saraux A; Tison A; Cornec D; Dueymes M; Foulquier N; Hillion S; Roguedas-Contios AM; Benyoussef AA; Alarcon-Riquelme ME; Pers JO; Devauchelle-Pensec V;
    Arthritis Rheumatol; 2024 May; 76(5):751-762. PubMed ID: 38130019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.